A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: Efficacy and pharmacokinetic data review.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing proprietary phase 1-3 trial data without systematic review methodology.
PubMed 28364869 · doi:10.1016/j.maturitas.2017.02.008
What was done
The authors reviewed efficacy, safety, and pharmacokinetic data from phase 1, phase 2 (NCT02449902), and phase 3 (REJOICE, NCT02253173) trials evaluating TX-004HR (a low-dose 17β-estradiol vaginal softgel capsule at 4 μg, 10 μg, and 25 μg) for vulvar and vaginal atrophy in postmenopausal women.
What was found
In phase 2 and 3 trials, TX-004HR significantly improved vaginal cytology (superficial and parabasal cells) and vaginal pH, while phase 3 demonstrated reduced dyspareunia, vaginal dryness, and vulvar/vaginal itching or irritation (no specific numerical efficacy values reported in abstract). In two phase 1 trials, estradiol Cmax and AUC0-24 were significantly lower with 10 μg and 25 μg TX-004HR than with equivalent approved vaginal estradiol tablets. In a REJOICE substudy (n=72), estradiol Cavg and AUC0-24 for the 4 μg and 10 μg doses did not differ from placebo on days 1 and 14. The 25 μg dose produced higher Cavg and AUC0-24 than placebo on days 1 and 14, but levels remained within postmenopausal reference ranges. By day 84, estradiol concentrations across all three doses were indistinguishable from placebo, demonstrating no systemic accumulation.
Why it matters
This review highlights that ultra-low-dose vaginal softgel estradiol can treat local postmenopausal atrophy symptoms with negligible to minimal systemic estrogen exposure, potentially reassuring patients and clinicians concerned about systemic hormone risks.
Limits
The paper is an unsystematic narrative review, carrying inherent risks of selective reporting. The abstract omits precise numerical data, confidence intervals, and p-values for clinical efficacy endpoints. Total participant numbers across all reviewed trials were not stated, the pharmacokinetic substudy was small (n=72), and safety data beyond 84 days were not described.
Cited by
- context Intravaginally administered medications such as estradiol are rapidly absorbed through vaginal tissue and can be measured in the bloodstream within minutes.